SEVERE PERTUSSIS IN CHILDHOOD: UPDATE AND CONTROVERSY - SYSTEMATIC REVIEW

ABSTRACT Objective: Through a systematic review, this essay aimed at revising the concepts of severe pertussis, updating the epidemiology, pathophysiology, clinical presentation, antibiotic therapy and auxiliary therapeutic options for symptomatology and complications. Data sources: This review considered publications from the last 30years in the databases US National Library of Medicine (PubMed), Scientific Electronic Library Online (SciELO), Literatura Latino-americana e do Caribe em Ciências da Saúde (LILACS), Cochrane, Google Scholar, as well as protocols of the Ministry of Health and recommendations of the Centers for Disease Control and Prevention, related to childhood pertussis (whooping cough), with emphasis on its severe form. This research was based on keywords derived from the terms “pertussis”, “azithromycin”, “antitussives”, “leukocyte reduction” in Portuguese and English. Duplicate studies and those with unavailable full-text were excluded. Data synthesis: Among 556 records found, 54 were selected for analysis. Pertussis, as a reemerging disease, has affected all age groups, evidencing the transient immunity conferred by infection and vaccination. Severe cases occur in neonates and infants, with secondary viral and bacterial complications and malignant pertussis, a longside hyperleukocytosis, respiratory failure and shock. Macrolides continue to be the chosen antibiotics, while antitussives for coughing remain without efficacy. The prompt treatment in Intensive Care Units improved the prognostic in severe cases, and transfusion was promising among procedures for leukoreduction. Conclusions: Approaching severe pertussis in childhood remains a challenge for diagnostic and therapy, as the available therapeutic options are still unsatisfactory. Strategies of prevention are expected to reduce the occurrence of severe cases, while new studies should confirm the role of auxiliary therapies.

[1]  F. Ramalho,et al.  Severe pertussis infection , 2017, Medicine.

[2]  M. Kazantzi,et al.  Characteristics of Bordetella pertussis infection among infantsand children admitted to paediatric intensive care units in Greece: A multicentre, 11‐year study , 2017, Journal of paediatrics and child health.

[3]  M. Zlamy Rediscovering Pertussis , 2016, Front. Pediatr..

[4]  P. Kilgore,et al.  Pertussis: Microbiology, Disease, Treatment, and Prevention , 2016, Clinical Microbiology Reviews.

[5]  N. Carbonetti,et al.  Novel therapies for the treatment of pertussis disease. , 2015, Pathogens and disease.

[6]  M. L. Penkal,et al.  Resurgence of pertussis at the age of vaccination: clinical, epidemiological, and molecular aspects. , 2015, Jornal de pediatria.

[7]  H. Marshall,et al.  Predictors of Disease Severity in Children Hospitalized for Pertussis During an Epidemic , 2015, The Pediatric infectious disease journal.

[8]  U. Heininger,et al.  Antibiotic treatment of pertussis: are 7 days really sufficient? , 2015, The Pediatric infectious disease journal.

[9]  D. Fisman,et al.  Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysis , 2015, Pediatrics.

[10]  S. Amantéa,et al.  Clinical, laboratorial and radiographic predictors of Bordetella pertussis infection☆ , 2014, Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo.

[11]  A. Cruz,et al.  Trends in hospitalizations and resource utilization for pediatric pertussis. , 2014, Hospital pediatrics.

[12]  W. Schaffner,et al.  Can we conquer coqueluche? , 2014, The Journal of infectious diseases.

[13]  B. Feenstra,et al.  Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study , 2014, BMJ : British Medical Journal.

[14]  T. Carvalhanas,et al.  Serodiagnosis as Adjunct Assay for Pertussis Infection in São Paulo, Brazil , 2014, Clinical and Vaccine Immunology.

[15]  M. Korppi Whooping cough--still a challenge. , 2013, Jornal de pediatria.

[16]  J. Cherry Pertussis: Challenges Today and for the Future , 2013, PLoS pathogens.

[17]  J. Cherry,et al.  Exchange Blood Transfusion in the Management of Severe Pertussis in Young Infants , 2013, The Pediatric infectious disease journal.

[18]  Carol E. Nicholson,et al.  Critical Pertussis Illness in Children: A Multicenter Prospective Cohort Study* , 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[19]  何巍 美国疾病预防控制中心(Centers for Diseases Control and Prevention,CDC):美国流感季节到来 , 2011 .

[20]  K. Harrington,et al.  Impact of Rapid Leukodepletion on the Outcome of Severe Clinical Pertussis in Young Infants , 2010, Pediatrics.

[21]  H. Smaoui,et al.  [Malignant pertussis: an underdiagnosed illness]. , 2010, Medecine tropicale : revue du Corps de sante colonial.

[22]  R. Perera,et al.  Symptomatic treatment of the cough in whooping cough. , 2010, The Cochrane database of systematic reviews.

[23]  Nicholas Wood,et al.  Pertussis: review of epidemiology, diagnosis, management and prevention. , 2008, Paediatric respiratory reviews.

[24]  R. Holman,et al.  Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  S. Pelton,et al.  Frequency of pertussis in children with prolongued cough , 2008, Scandinavian journal of infectious diseases.

[26]  N. Curtis,et al.  Antibiotics for whooping cough (pertussis). , 2007, The Cochrane database of systematic reviews.

[27]  E. Segedin,et al.  Pertussis requiring intensive care , 2007, Archives of Disease in Childhood.

[28]  K. Edwards,et al.  Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure , 2006, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[29]  F. Muñoz Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. , 2006, Seminars in pediatric infectious diseases.

[30]  T. Murphy,et al.  Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[31]  Seema Mattoo,et al.  Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies , 2005, Clinical Microbiology Reviews.

[32]  M. J. Romano,et al.  Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. , 2004, Pediatrics.

[33]  J. Langley,et al.  Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. , 2004, Pediatrics.

[34]  E. Elliott,et al.  National study of infants hospitalized with pertussis in the acellular vaccine era , 2004, The Pediatric infectious disease journal.

[35]  K. Edwards,et al.  Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? , 2003, Pediatrics.

[36]  S. Halperin,et al.  Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. , 2003, The Journal of pediatrics.

[37]  S. Mehra,et al.  Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. , 2001, The Pediatric infectious disease journal.

[38]  C. Guzmán,et al.  The virulence factors of Bordetella pertussis: a matter of control. , 2001, FEMS microbiology reviews.

[39]  M. Loeffelholz,et al.  Real-Time PCR Assay Targeting IS481of Bordetella pertussis and Molecular Basis for Detecting Bordetella holmesii , 2001, Journal of Clinical Microbiology.

[40]  C. Locht Molecular aspects of Bordetella pertussis pathogenesis. , 1999, International microbiology : the official journal of the Spanish Society for Microbiology.

[41]  J. Cherry,et al.  Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. , 1997, Pediatrics.

[42]  E. Korgenski,et al.  Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States , 1997, Journal of clinical microbiology.

[43]  F. Müller,et al.  Laboratory diagnosis of pertussis: state of the art in 1997 , 1997, Journal of clinical microbiology.

[44]  J. Langley,et al.  Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. , 1997, Pediatrics.

[45]  I. Onorato,et al.  Laboratory diagnosis of pertussis: the state of the art , 1987, The Pediatric infectious disease journal.

[46]  J. W. Bass Erythromycin for treatment and prevention of pertussis , 1986, Pediatric infectious disease.

[47]  P. Gilligan,et al.  Importance of culture in laboratory diagnosis of Bordetella pertussis infections , 1984, Journal of clinical microbiology.

[48]  J. Regan,et al.  Enrichment medium for the isolation of Bordetella , 1977, Journal of clinical microbiology.